

Headline: Health Revival Partners has a robust, low-cost, easily implemented solution to the global chronic disease crisis called “4-Dimensions of Health.”

Simplistic Explanation: The Standard-of-Care (standard medical practice) measures acute health status mainly, yet chronic diseases drive most costs, morbidity (disease) and early mortality. We have developed a detailed measurement for chronic health status that is connected to actionable steps to improve that status.

Scope: The global healthcare system is reactive to sudden, acute illness. However, 90% of medical costs are due to slowly incubating chronic conditions according to the CDC. The U.S. has an immediate need to start reversing chronic disease. America spends 250% more on healthcare per capita yet our people live 2.5 years less compared to the other most developed nations. **

Important Facts:

- 5% of any population drive 60% of healthcare costs, thus the scope of a population solution is tenable.
- Over 60% of people who are high cost medical claimants this year were actually low-cost claimants last year. Claims data, usually relied upon to determine “next years” high risk fails 60% of the time. Our solution significantly improves predictions
- “Big Data” is largely inconsequential as proven by the COVID-19 pandemic where essentially no solutions have been promoted through this technology. The reason is the data being gathered is not high impact. Our solution changes that.

Our Answer: We have a “funnel” approach to determining population and individual need. Importantly, each step (dimension) of our diagnostic analytics are linked, through AI, to personalized, precision, and population-based solutions to prevent and reverse chronic diseases, including COVID-19 (we just published a paper demonstrating the approach <https://bit.ly/2TNGtpk>).

Approach: We developed, and currently implement a “4-dimensions of health” strategy. The key concept is the health of every human can be accurately defined by where they lie on **4 continuums of health**: Dimension 1: Determinants of Health (life risk factors); Dimension 2: Physiology Scale (biomarkers); Dimension 3: Pathology Scale (imaging data); and Dimension 4: Current Morbidity Status (diagnoses and pharma use). The status of each, thus an individual’s position on the 4 health continuums, and on an aggregate continuum, are easily and inexpensively measured within our system.

Dimension 1: On-line survey with advanced AI and links to interventions.

Dimension 2: Low-cost lab panel available through major lab services organization. Panel and interpretation based on chronic outcomes and early mortality risk.

Dimension 3: Measurement of pathology (tissue) changes through a comprehensive eye exam and other imaging technologies.

Dimension 4: Determination of health status through CPT code analysis and medication usage.

Proven Outcomes: We reverse (and prevent) usual, complex, and ill-defined conditions:

<https://www.healthrevivalpartners.com/case-studies>

Relevance to Current and Future Pandemics: The Chinese have analyzed COVID-19 sufferers and found that those who died or had the most severe conditions suffered from a “cytokine storm.” Simply put, this is profound inflammation. Harvard Medical School adopted the Chinese lab panel for a “cytokine storm” to risk stratify (triage) COVID-19 in-hospital patients at Mass General. Our Dimension 2 panel, that we have been using for 30 years, includes all the tests considered important for characterizing COVID-19 and additional inflammatory markers that neither the Chinese nor Harvard have measured in these patients. While Harvard is using this panel to triage late-stage patients, we are using a more robust panel to “triage” (risk stratify) populations regardless of presumed health status. This approach is applicable to “return to work” programs. <https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf>

Pricing: We are priced similarly to a wellness program. When appropriate and agreeable, we invoke intensive testing and interventions on the 5-10% of high risk and high cost members of your population. We have shown that this is an important component to creating a high ROI.

Key Contributors: Harvard Medical School faculty and MIT medical scientist

** <https://www.oecd.org/health/health-data.htm>